New agile solutions to accelerate digital supply chain transformation
New solutions will provide critical transparency to the life sciences supply chain, mobilizing companies to rapidly react to unforeseen disruptions and ensure medicine supply.
TraceLink, a leading digital platform company for the life sciences industry, has announced a new package of agile solutions designed to digitalize the pharmaceutical supply chain.
In response to COVID-19, TraceLink has "urgently" prioritized its focus on delivering solutions that will have an immediate impact in helping companies to meet unforeseen supply chain challenges and ensure the safe delivery of critical medicines and supplies to their patients.
Available on TraceLink’s Opus platform, the new agile solutions tap into TraceLink’s end-to-end network connectivity, data sharing, and multi-party process orchestration, giving companies the visibility and responsiveness needed for their supply chains to thrive in today’s challenging environment.
The centralized network-based system identifies, tracks and resolves supply partner issues in real-time. Agile Issue Management connects internal teams with external suppliers and downstream customers to manage unforeseen supply chain disruptions and resolve them faster.
When supply and demand experience massive fluctuation, drug shortages are inevitable. By leveraging the power of TraceLink’s network data and advanced analytics, TraceLink’s Drug Shortage Intelligence solution provides network-wide insights into supply and patient demand, allowing customers to accurately predict and prevent drug shortages, ensuring critical medicines are available to every patient.
By integrating Internet of Things with product serialization, this solution will provide full track and trace visibility for the secure delivery of vaccines, test kits and high-value products.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.